Praxis Precision Medicines general counsel sells $4.8m in shares
BURLINGTON, Mass. - On Friday, Azenta, Inc. (NASDAQ:AZTA) reported fourth-quarter results that exceeded analyst expectations, with improved margins and solid revenue growth.
The life sciences company’s shares gained 1.42% in pre-market trading after the results.
The company posted adjusted earnings per share of $0.21 for its fiscal fourth quarter, beating the analyst consensus of $0.19. Revenue reached $159 million, surpassing estimates of $156.46 million and representing a 6% increase from the same period last year. On an organic basis, revenue grew 4% year-over-year.
Azenta’s Multiomics segment was the standout performer, with revenue increasing 11% to $73 million, while Sample Management Solutions revenue rose 2% to $86 million. The company also showed significant improvement in profitability, with adjusted EBITDA of $21 million and an adjusted EBITDA margin of 13.0%, up 230 basis points from the prior year.
"Fiscal 2025 was a transformative year for Azenta. We achieved 3% core revenue growth and meaningful margin expansion," said John Marotta, President and Chief Executive Officer. "We simplified our organization, made significant progress enabled by the Azenta Business System, and strengthened our execution, which is driving measurable improvements in quality, delivery, and productivity."
Looking ahead, Azenta provided an optimistic outlook for fiscal 2026, projecting organic revenue growth of 3% to 5% and approximately 300 basis points of adjusted EBITDA margin expansion.
The company ended fiscal 2025 with a strong balance sheet, reporting $546 million in cash, cash equivalents, restricted cash, and marketable securities. Capital expenditures for the full year totaled $34 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.